Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Phase 1
Not yet recruiting
Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
Biological: Synthetic long peptide personalized cancer vaccine
Drug: Poly ICLC
Biological: Nivolumab
Device: Signatera assay
Subscribe
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
16
Registration Number
NCT06529822
Locations
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy